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More than a century ago, Paul Ehrlich demonstrated in a set
of dye experiments the lack of permeability of intracerebral
vessels to albumin-binding dyes and therefore postulated a
barrierbetweenbloodandneuronaltissue.Indeed,transport
acrosstheblood-brainbarrier(BBB)istightlyregulatedbyat
least four diﬀerent cells that comprise the brain microvascu-
lature: the endothelial cell and highly speciﬁc tight junctions
between them, the pericytes whichshare with the endothelial
cellsacommoncapillarybasementmembrane,theastrocytic
foot processes which cover the capillaries, and nerve endings
which innervate the vessels. Importantly, dysfunction of the
BBB occurs during numerous common neurological dis-
eases, including stroke, epilepsy, trauma, tumors, and infec-
tiousanddegenerativediseases.Whileithasbeenlongrecog-
nized that BBB dysfunction is associated with brain diseases,
only recently it has been suggested to play a role in the
pathogenesisofneuronalnetworksdysfunctionanddegener-
ation. In this special issue clinical and experimental evidence
for the involvement of BBB dysfunction in the pathogenesis
of seizures and epilepsy (N. Marchi et al. “the etiological role
of blood-brain barrier dysfunction in seizure disorders”a n d
L. M. Gibson et al. in “Occult cerebrovascular disease and
lateonset epilepsy: could loss of neurovascular unit integrity be
av i a b l em o d e l ? ”), posttraumatic epilepsy (O. Tomkins et al.
in “Blood-brain barrier breakdown following traumatic brain
injury: a possible role in posttraumatic epilepsy”), Alzheimer’s
diseases(V.C.Andersonetal.in“Theblood-brainbarrierand
microvascular water exchange in Alzheimer’s disease”), and
psychiatric disorders (Y. Serlin et al. in “Vascular pathology
and blood-brain barrier disruption in cognitive and psychiatric
complications of type 2 diabetes mellitus”) is given. Experi-
mental evidence points to the mechanisms involved, which
most importantly seems to include astroglial activation and
disturbance of the extracellular milieu, speciﬁcally altered
homeostasis of water and electrolytes (V. C. Anderson et al.
in “The blood-brain barrier and microvascular water exchange
in Alzheimer’s disease”). In addition, immune response and
inﬂammation seems to have closed bidirectional interactions
with disturbed BBB permeability (H. B. Stolp et al. in “Ef-
fects of neonatal systemic inﬂammation on blood-brain barrier
permeability and behaviour in juvenile and adult rats,” A.
S. Haqqani and D. B. Stanimirovic in “Intercellular interac-
tomics of human brain endothelial cells and Th17 lymphocytes:
a novel strategy for identifying therapeutic targets of CNS
inﬂammation,” a n dA .R .F r i e d m a ne ta l .i n“Elucidating the
complex interactions between stress and epileptogenic path-
ways”).
The accumulating experimental evidence for BBB in-
volvement in the pathogenesis and progression of these com-
mon neurological diseases raises important unresolved ques-
tions of how similar vascular dysfunction can lead to wide
range of neurological symptoms and signs. While the
answers to these key questions are not yet known, papers
in this special issue tackle some of the potential variables
including the localization, extent, and duration of BBB dys-
function (Y. Serlin et al. in “Vascular pathology and blood-
brain barrier disruption in cognitive and psychiatric complica-
tions of type 2 diabetes mellitus”), the time point during de-
velopment (H. B. Stolp et al. in “Eﬀects of neonatal sys-
temic inﬂammation on blood-brain barrier permeability and2 Cardiovascular Psychiatry and Neurology
b e h a v i o u ri nj u v e n i l ea n da d u l tr a t s ” ) and aging (L. M.
Gibson et al. in “Occult cerebrovascular disease and late-onset
epilepsy: could loss of neurovascular unit integrity be a viable
model?”) in which disturbance occurs, and the interaction
with confounding factors such as stress in early life or in
adulthood (A. R. Friedman et al. in “Elucidating the com-
plex interactions between stress and epileptogenic pathways”).
These open questions raise the need for the development of
new methods for the study of BBB dysfunction exvivo—as
described by R. Kov´ acs and colleagues (in “Slice cultures as a
model to study neurovascular coupling and blood brain barrier
in vitro”). Furthermore, it becomes clear that methods for
the quantitative and reliable evaluation of BBB permeability
are lacking. In this respect, new imaging approaches in
experimental animals (D. Jorks et al. in “A novel algorithm for
theassessmentofblood-brainbarrierpermeabilitysuggeststhat
brain topical application of endothelin-1 does not cause early
opening of the barrier in rats”) and in humans (O. Tomkins
et al. in “Blood-brain barrier breakdown following traumatic
brain injury: a possible role in posttraumatic epilepsy” and
V. C. Anderson et al. in “The blood-brain barrier and mi-
crovascular water exchange in Alzheimer’s disease”)a r ep r e -
sented as part of the ongoing eﬀort to allow the diagnosis,
followup,andevaluationoftheintegrityoftheneurovascular
unit andBBB functions. Finally, thenew conceptsandmech-
anisms described recently in the literature highlight the neu-
rovascular unit including speciﬁcally brain vessels and im-
mune system as new therapeutic targets for the prevention
and treatment of neurological diseases. Novel approaches
for the identiﬁcation of new targets based on complex ge-
nomic, proteomic, and interactomics tools are presented
by A. S. Haqqani and D. B. Stanimirovic (in “Intercellular
interactomics of human brain endothelial cells and Th17
lymphocytes: a novel strategy for identifying therapeutic targets
of CNS inﬂammation”).
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